Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation
Holger Babbe,Thomas B Sundberg,Mark Tichenor,Mark Seierstad,Genesis Bacani,James Berstler,Wenying Chai,Leon Chang,De Michael Chung,Kevin Coe,Bernard Collins,Michael Finley,Alexander Guletsky,Christopher T Lemke,Puiying A Mak,Ashok Mathur,Eduardo V Mercado-Marin,Shailesh Metkar,Donald D Raymond,Marie-Laure Rives,Michele Rizzolio,Paul L Shaffer,Russell Smith,Jacqueline Smith,Ruth Steele,Helena Steffens,Javier Suarez,Gaochao Tian,Nathan Majewski,Laurie P Volak,Jianmei Wei,Prerak T Desai,Luvena L Ong,Tatiana Koudriakova,Steven D Goldberg,Gavin Hirst,Virendar K Kaushik,Tatiana Ort,Nilufer Seth,Daniel B Graham,Scott Plevy,Jennifer D Venable,Ramnik J Xavier,Jennifer E Towne
DOI: https://doi.org/10.1073/pnas.2307086120
2024-01-02
Abstract:The salt-inducible kinases (SIK) 1-3 are key regulators of pro- versus anti-inflammatory cytokine responses during innate immune activation. The lack of highly SIK-family or SIK isoform-selective inhibitors suitable for repeat, oral dosing has limited the study of the optimal SIK isoform selectivity profile for suppressing inflammation in vivo. To overcome this challenge, we devised a structure-based design strategy for developing potent SIK inhibitors that are highly selective against other kinases by engaging two differentiating features of the SIK catalytic site. This effort resulted in SIK1/2-selective probes that inhibit key intracellular proximal signaling events including reducing phosphorylation of the SIK substrate cAMP response element binding protein (CREB) regulated transcription coactivator 3 (CRTC3) as detected with an internally generated phospho-Ser329-CRTC3-specific antibody. These inhibitors also suppress production of pro-inflammatory cytokines while inducing anti-inflammatory interleukin-10 in activated human and murine myeloid cells and in mice following a lipopolysaccharide challenge. Oral dosing of these compounds ameliorates disease in a murine colitis model. These findings define an approach to generate highly selective SIK1/2 inhibitors and establish that targeting these isoforms may be a useful strategy to suppress pathological inflammation.